Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Elicio Therapeutics (ELTX) Revenue (2020 - 2022)

Elicio Therapeutics filings provide 3 years of Revenue readings, the most recent being $653000.0 for Q2 2022.

  • On a quarterly basis, Revenue rose 20.93% to $653000.0 in Q2 2022 year-over-year; TTM through Mar 2023 was $653000.0, a 97.73% decrease, with the full-year FY2022 number at $2.3 million, down 91.63% from a year prior.
  • Revenue hit $653000.0 in Q2 2022 for Elicio Therapeutics, down from $1.6 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $25.1 million in Q4 2021 to a low of -$2.2 million in Q4 2020.
  • Median Revenue over the past 3 years was $729000.0 (2020), compared with a mean of $3.2 million.
  • The widest YoY moves for Revenue: up 1228.14% in 2021, down 25.93% in 2021.
  • Elicio Therapeutics' Revenue stood at -$2.2 million in 2020, then skyrocketed by 1228.14% to $25.1 million in 2021, then crashed by 97.4% to $653000.0 in 2022.
  • The last three reported values for Revenue were $653000.0 (Q2 2022), $1.6 million (Q1 2022), and $25.1 million (Q4 2021) per Business Quant data.